Skip to content

Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study

Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07449897
Acronym
Bilnor
Enrollment
340
Registered
2026-03-04
Start date
2026-02-01
Completion date
2036-12-01
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Stones

Brief summary

The BILNOR study is a prospective multicenter observational study evaluating how common bile duct stones are best managed in patients undergoing cholecystectomy. The study focuses particularly on transcystic laparoscopic common bile duct exploration (LCBDE) and assesses stone clearance, technical success, complications, and health-economic outcomes in routine clinical practice. A secondary aim is to compare LCBDE with intraoperative ERCP regarding efficacy, complication rates, and costs. Approximately 340 patients from several Norwegian centers are planned to be included starting in March 2026.

Detailed description

The BILNOR study (Cholecystectomy with intraoperative management of bile duct stones in Norway) is a prospective, multicenter observational study evaluating how common bile duct stones (CBDS) are best managed when patients also need a cholecystectomy. Although ERCP followed by later cholecystectomy is still the most frequently used strategy, it often requires two separate procedures, with additional discomfort, risk, admissions, and costs. Single-stage alternatives-either intraoperative ERCP (including rendezvous techniques) or laparoscopic common bile duct exploration (LCBDE)-may reduce resource use and improve the patient pathway, but are unevenly available across Norwegian hospitals and have differing complication profiles. The primary focus of BILNOR is transcystic LCBDE, a technique implemented at Oslo University Hospital in 2019 using a structured "step-up" approach (e.g., saline flushing, pharmacologic relaxation, guidewire passage, papillary balloon dilatation up to 8 mm, and transcystic choledochoscopy with stone extraction; intraoperative ERCP if needed/available). The study will estimate real-world stone clearance (defined as no repeat biliary intervention within 90 days), technical success (intraoperative clearance on cholangiography), and 30-day complications including a study-specific definition of post-procedure pancreatitis, as well as bile leak and other Clavien-Dindo graded events. Health economic outcomes (length of stay and costs per patient) and which procedural steps are most often required to achieve clearance are also assessed. A secondary aim is to compare LCBDE with intraoperative ERCP regarding efficacy, complication rates, and costs, including a non-inferiority assessment for stone clearance. The planned total sample size is approximately 340 patients (155 per group plus allowae for dropouts). Learning-curve effects will be addressed with center-level sensitivity analyses excluding early cases. Inclusion is planned to start March 1, 2026, with expansion to additional centers as the technique spreads in Norway.

Interventions

None listed

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years * Preoperatively image proven choledocholithiasis or bile duct sludge (US / CT / MRI) * ≤ 8 mm size * ≤ 5 stones * Not proximal bile duct stones * Planned cholecystectomy with intraoperative bile duct clearance (LCBDE or intraoperative ERCP)

Exclusion criteria

* Previous cholecystectomy * Medically unfit for surgery (frailty, comorbidity) * Technically inoperable (hostile abdomen, inflammatory processes, bleeding conditions, cirrhosis) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Reintervention rate90 daysBile duct reintervention rate

Countries

Norway

Contacts

CONTACTMagnus H Fasting, MD, PhD, FEBS (UGI)
magfas@ous-hf.no0047 22800000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026